Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc. (BLPH) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
blph · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bellerophon Therapeutics, Inc. (BLPH) measures how much investors pay for each dollar of the company's trailing earnings. BLPH's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$2.08.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2012 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bellerophon Therapeutics, Inc.You BLPH | $0M | N/A | — | -$2.08 |
 Atlantic International Corp. ATLN | $61M | N/A | — | -$1.08 |
 BioCardia, Inc. BCDA | $5M | N/A | — | -$1.23 |
 Histogen Inc. HSTO | $0M | N/A | — | -$3.31 |
 Immatics N.V. IMTX | $1.2B | N/A | — | -$1.61 |
 Akerna Corp. KERN | $0M | N/A | — | -$0.00 |
 Seelos Therapeutics, Inc. SEEL | $0M | N/A | — | -$7.73 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-2.08 | — | |
2021-12-31 FY2021 | — | $-1.87 | — | |
2020-12-31 FY2020 | — | $-3.17 | — | |
2019-12-31 FY2019 | — | $-2.95 | — | |
2018-12-31 FY2018 | 18.52x | $0.65 | — | |
2017-12-31 FY2017 | — | $-21.11 | — | |
2016-12-31 FY2016 | — | $-3.17 | — | |
2015-12-31 FY2015 | — | $-6.18 | — | |
2014-12-31 FY2014 | — | $-5.01 | — | |
2013-12-31 FY2013 | — | $-4.80 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bellerophon Therapeutics, Inc. (BLPH) measures how much investors pay for each dollar of the company's trailing earnings. BLPH's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$2.08.
Frequently asked questions
BLPH pe ratio · 6 questionsBLPH's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.01 and TTM EPS of -$2.08. Data sourced from Financial Modeling Prep via BLPH's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bellerophon Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09